
    
      This phase I trial will escalate doses of the histone deacetylase inhibitor (HDAC) vorinostat
      to a chemoradiation platform for cisplatin, pemetrexed and radiation to a dose of 70Gy in
      NSCLC patients with unresectable IIIA and dry IIIB disease. The endpoint will be to determine
      MTD of the combination.
    
  